The NexEos Bio management team and NexEos’ collaborators at The University of Utah include highly-seasoned biopharmaceutical professionals with several decades of experience in both the field of eosinophil research and pharmaceutical development and commercialization. Scientific Founder and Chief Scientific Officer Gerald Gleich, MD, was the clinical investigator who first identified and characterized the major proteins of the distinctive eosinophil granules and described several novel clinical syndromes, including Episodic Angioedema with Eosinophilia (EAE), which is also known as Gleich Syndrome. Other collaborators on the team actively manage patients with EoE in their clinical practices. A number of team members have been leaders in the development of therapeutics for the treatment of a host of eosinophil-mediated disorders including EoE, eosinophil-mediated asthma and the hypereosinophilic syndrome (HES). Collectively, they have brought several programs successfully through U.S. Food & Drug Administration (FDA) approval and to the market to further science and improve patients’ lives.
"Many NexEos executive team members have been leaders in the development of therapeutics for the treatment of a host of eosinophil-mediated disorders. Collectively, we have brought several programs successfully through FDA approval and to the market to further science and improve patients’ lives. We look forward to doing the same on the diagnostics side here at NexEos."
Theresa Mansi, Chief Executive Officer
Chief Executive Officer
Theresa Mansi has served as Chief Executive Officer and member of the Board of Directors at NexEos since its inception in 2019. Over 30 years in the pharmaceutical and biotech industry, Theresa’s accomplishments have spanned Global Business Development, Ventures, Product Development, Strategic Marketing and Market Research. Formerly, Theresa was Vice President of the Global Business Insights division of DRG, the premier provider of healthcare data and insights. Prior to DRG, Theresa worked for GSK for more than 20 years in roles of increasing responsibility. As Senior Director Worldwide Business Development, she negotiated complex deals, closing several U.S., Japanese and European licensing and M&A deals. Theresa also headed GSK’s Ventures group where she led a team of entrepreneurs who created start-up companies with funding from a variety of sources. Early on, Theresa established GSK’s Global Marketing Research department while living in London. Theresa is a Certified Licensing Professional with an MBA in International Marketing from Saint Joseph’s University. She has completed Executive Education Programs at Darden University and the Wharton School.
Gerald Gleich, MD
Co-Founder & Chief Scientific Officer
Dr. Jerry Gleich has had a life-long passion and professional commitment to understanding the eosinophil in human biology. This interest began during his residency training and was stimulated by caring for patients with bronchial asthma hospitalized at Mayo Clinic. The focus of his work on the eosinophil has been on the distinctive granules. He and his colleagues have isolated, characterized, identified the cDNAs and the genes, and established assays for measurement and localization of all of the granule proteins. In turn, these efforts led to the recognition that eosinophil degranulation with release of cytotoxic and cytostimulatory cationic molecules into tissues is characteristic of eosinophil-related diseases. These efforts also led to the recognition of several novel syndromes, including episodic angioedema associated with eosinophilia (Gleich syndrome) and the eosinophil-myalgia syndrome.
Jerry received his medical degree from the University of Michigan. He obtained residency training in Internal Medicine at the Philadelphia General Hospital and the Jackson Memorial Hospital at the University of Miami and was a flight surgeon in the United States Air Force. He received postdoctoral training at the University of Rochester and then established a research laboratory for allergic diseases at the Mayo Clinic. While at Mayo, he was Professor of Medicine and Immunology, Chairman of the Department of Immunology. Jerry is an emeritus Professor of Pediatrics at Primary Children’s Medical Center in Salt Lake City, Utah, and has had an allergy medicine practice for 11 years at the Veterans Administration Medical Center in Salt Lake City, Utah. Presently, he is Professor of Dermatology and Medicine at The University of Utah as well as a founder and Chief Scientific Officer of NexEos Bio.
Jerry has served as Chairman of the World Health Organization Subcommittee on Standardization of Allergens, on the Allergy and Clinical Immunology Research Committee of the National Institute of Allergy and Infectious Diseases, on the editorial board of Journal of Allergy And Clinical Immunology, on the editorial board of the Journal of Immunology, as Member and Chairman of the Board of Scientific Counselors, National Institute of Allergy and Infectious Diseases (NIAID), and as Member and Chair of the Data and Safety Monitoring Board of NIAID. Jerry is a charter member and past president of the International Eosinophil Society (IES). He is a medical advisor to the American Partnership for Eosinophilic Disorders (APFED) Board of Directors.
Andrea Vresilovic MS,PMP
Clinical Development & Project Management
Andrea has 20 years of experience across clinical research and drug development. During her 15 years at Merck, she progressed through roles in clinical sciences, operations, and project management, serving in therapeutic areas including neuroscience, oncology, cardiovascular and vaccines. Andrea led projects and product teams through multiple stages of development, including expansion of product development and agency approvals, not only in the Unites States, but also in European an Asia-Pacific markets. Driving strategy and execution for both internal and partnered products, she provided leadership, clinical development, and project management expertise to her team to ensure successful end-to-end strategies for such brands as Keytruda, Gardasil, and Vaxelis.
Prior to her time in the pharmaceutical industry, Andrea was at the Children's Hospital of Philadelphia working on an NIH grant for bone density research. Andrea is certified as a Project Management Professional (PMP). She earned her MS in human Nutrition from University of Delaware and a BS in Nutrition from Pennsylvania State University.
Kelly has more than 20 years of experience working in the healthcare industry, primarily in the development of pharmaceutical products. She spent six years with GlaxoSmithKline providing commercial strategy and product development support to programs from pre-clinical stages of development through to global registration. Over the past 13 years, Kelly has been working with small teams of seasoned drug developers to identify promising assets, build companies around them, raise funding, design and implement strategic development plans and drive the companies to successful outcomes for both the products as well as investors. She has been a founding team member of seven biotech start-ups – three of which have led to product approvals and four to a successful exit for investors. In addition, Kelly has spent a number of years working in the space of eosinophil-mediated disease – working as a key team member on two products that have been approved in the US and Europe for the treatment of eosinophil-mediated conditions. In addition to her role with NexEos, Kelly is a partner with NeXeption.
Previously, Kelly served as the Vice President of Commercial Strategy for Onspira Therapeutics, Inc. (acquired by Altavant Sciences), Vice President of Product Strategy and Marketing for Ceptaris Therapeutics (acquired by Actelion) and Vice President of Product Strategy and Business Development for Ception Therapeutics (acquired by Cephalon), Aclaris Therapeutics (IPO 2015), Ralexar Therapeutics and Velicept Therapeutics. She earned her MS in Health Services Administration and a BS from the University of Michigan. Additionally, she completed a post-graduate fellowship with Henry Ford Health System.
Jennifer has 14 years of experience in the biotech industry. Her biotech career started with Ception Therapeutics as a Senior Accountant. Following Ception, she owned and operated her own accounting business, DanJenn, Inc. where she continued to work for various start-up biotech companies (Ceptaris Therapeutics, Inc., Velicept Therapeutics, Inc. and Onspira Therapeutics, Inc.) on a consulting basis. Jennifer worked alongside the company's CFO by maintaining accounting records, assisting auditors, and reviewing prepared tax returns. Through DanJenn, she has worked with various types of businesses offering account management and tax return preparation. Jennifer has her bachelor's degree in Accounting from Ursinus College.